<DOC>
	<DOCNO>NCT02715531</DOCNO>
	<brief_summary>This study evaluate safety , tolerability pharmacokinetic variability atezolizumab combination bevacizumab , bevacizumab + oxaliplatin , leucovorin 5-fluorouracil ( 5-FU ) ( FOLFOX ) , vanucizumab , nab-paclitaxel + gemcitabine , FOLFOX , 5-FU + cisplatin .</brief_summary>
	<brief_title>A Study Safety Tolerability Atezolizumab Administered Combination With Bevacizumab and/or Other Treatments Participants With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>General Inclusion criterion Measurable disease per RECIST v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate hematologic end organ function Resolution acute , clinically significant treatmentrelated toxicity prior therapy Grade le equal ( &lt; /= ) 1 prior study entry , exception alopecia Ready use reliable contraceptive procedure Inclusion Criteria Specific HCC ( Arm A Arm D ) : Participants advance metastatic and/or unresectable HCC The participant disease amenable curative approach No prior line systemic therapy ( include participant sorafenibna√Øve ) Willing undergo fresh liver biopsy provide archival tissue take great ( &gt; ) 6 month Cycle 1 Day 1 ChildPugh Score B7 Serum bilirubin &lt; /= 3 time upper limit normal ( x ULN ) International normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) &lt; /= 2 x ULN Albumin &gt; 2.8 gram per deciliter ( g/dL ) Documented virology status hepatitis , confirm screen hepatitis B surface antigen ( HBsAg ) , antibody hepatitis B core antigen ( antiHBc ) , and/or antihepatitis C virus ( antiHCV ) Antiviral therapy per local standardofcare active hepatitis B virus ( HBV ) Inclusion Criteria Specific Gastric Cancer ( Arm B ) Histologically cytologically confirm locally advanced metastatic adenocarcinoma stomach GEJ participant receive prior systemic therapy metastatic disease Absence HER2 expression document situ hybridization ( ISH ) negative previously collect assessed tumor tissue upon initial diagnosis disease Inclusion criterion specific metastatic pancreatic cancer ( Arm C ) Histologically cytologically confirm metastatic adenocarcinoma pancreas No previous radiotherapy , surgery , chemotherapy , investigational therapy treatment metastatic disease Inclusion Criteria Specific mEC ( Arm E ) Histologically cytologically confirm locally mEC metastatic adenocarcinoma GEJ Siewert Classification Type I participants received prior systemic therapy primary metastatic disease chemoradiation therapy primary disease Absence HER2 expression document ISHnegative previously collect assessed tumor tissue upon initial diagnosis disease Willing undergo biopsy archival tissue available archival tissue take &gt; 6 month Cycle 1 Day 1 General Exclusion Criteria Uncontrolled pleural effusion , pericardial effusion , ascites Uncontrolled tumorrelated pain Uncontrolled hypercalcemia symptomatic hypercalcemia require continue use bisphosphonate therapy Known clinically significant liver disease , include active viral , alcoholic , hepatitis , cirrhosis , fatty liver , inherit liver disease ( exception participant Arm A Arm D ) Known primary central nervous system ( CNS ) malignancy untreated active CNS metastasis Known hypersensitivity biopharmaceuticals produce Chinese hamster ovary cell recombinant human antibody Positive test Human Immunodeficiency Virus ( HIV ) Active hepatitis B ( chronic acute ) , hepatitis C ( exception participant Arm A Arm D ) Active tuberculosis Severe infection within 4 week prior Day 1 Signs symptom significant infection within 2 week prior Day 1 Received oral IV antibiotic within 2 week prior Cycle 1 Day 1 Significant cardiovascular disease , New York Heart Association ( NYHA ) cardiac disease ( Class II great ) , myocardial infarction within 3 month prior Day 1 , unstable arrhythmia , unstable angina History stroke , reversible ischemic neurological defect transient ischemic attack within 6 month prior Day 1 Administration live , attenuate vaccine within 4 week Cycle 1 , Day 1 anticipation live attenuated vaccine require study Any serious medical condition abnormality clinical laboratory test , investigator judgment , preclude participant safe participation completion study Malignancies pancreatic carcinoma within 2 year prior study start , exception negligible risk metastasis death ( e.g. , expect 5year OS &gt; 90 % ) treat expected curative outcome ( adequately treat carcinoma situ cervix , basal squamous cell skin cancer , localize prostate cancer treat surgically curative intent , ductal carcinoma situ treat surgically curative intent ) Exclusion Criteria Related Medications Prior treatment anticytotoxic Tlymphocyteassociated protein 4 ( antiCTLA4 ) , antiprogrammed death1 ( antiPD1 ) , antiprogrammed death ligand1 ( antiPDL1 ) therapeutic antibody Treatment systemic immunostimulatory agent within 6 week five halflives drug , whichever longer , prior screen Treatment systemic corticosteroid immunosuppressive medication ( include limit prednisone , cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor [ TNF ] agent ) within 2 week prior Cycle 1 , Day 1 History severe allergic , anaphylactic , hypersensitivity reaction chimeric humanize antibody fusion proteins Participants prior allogeneic bone marrow transplantation prior solid organ transplantation Known allergy oxaliplatin ( platinum agent ) , leucovorin , 5FU , nabpaclitaxel ( taxanes ) gemcitabine Bevacizumab VanucizumabSpecific Exclusions ( Arms A , B , D ) Core biopsy minor surgical procedure , exclude placement vascular access device , within 3 day prior first dose bevacizumab vanucizumab History abdominal tracheoesophageal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within 6 month prior Day 1 History intestinal obstruction and/or clinical sign symptom GI obstruction within 6 month prior Day 1 Cycle 1 Clinical sign symptom GI obstruction requirement routine parenteral hydration , parenteral nutrition , tube feed Evidence abdominal free air explain paracentesis recent surgical procedure Serious , nonhealing dehisce wound , active ulcer , untreated bone fracture Proteinuria , demonstrate urine dipstick &gt; 1.0 g protein 24hour urine collection Metastatic disease involve major airway blood vessel , centrally locate mediastinal tumor mass large volume . HCC participant ( Arm A D ) vascular invasion portal hepatic vein may enrol History intraabdominal inflammatory process within 6 month prior Day 1 Cycle 1 Radiotherapy within 28 day abdominal/pelvic radiotherapy within 60 day prior Day 1 Cycle 1 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 Cycle 1 Chronic daily treatment nonsteroidal antiinflammatory drug ( NSAID ) Exclusions specific Arms A D ( HCC ) Participants untreated incompletely treated varix bleed highrisk bleed Treatment HCV antiviral therapy within 4 week prior Cycle 1 Day 1 Moderate severe ascites Hepatic encephalopathy Exclusions Specific Arm E ( Metastatic Esophageal Cancer ) HER2 expression define ISH positive and/or 3+ immunohistochemistry Prior chemotherapy treatment , include radiosensitization pre postoperative setting</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>